Filtered By:
Education: Study
Procedure: Heart Transplant
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 644 results found since Jan 2013.
Artificial Sweetener in Keto-Related Foods Tied to CV Risk Artificial Sweetener in Keto-Related Foods Tied to CV Risk
We need safety studies of long-term effects of artificial sweeteners in general, and erythritol specifically, on risks for heart attack and stroke, particularly in high-risk patients, says researcher.Medscape Medical News
Source: Medscape Pathology Headlines - February 28, 2023 Category: Pathology Tags: Cardiology News Source Type: news
Artificial sweetener linked to higher heart attack risk, study says
Participants with elevated levels of erythritol — used in low-calorie and keto products — had increased risk of heart attack, stroke or death, researchers found.
Source: Washington Post: To Your Health - February 28, 2023 Category: Consumer Health News Authors: Kelsey Ables Source Type: news
Could a Common Sweetener Raise Heart Risks?
MONDAY, Feb. 27, 2023 -- An artificial sweetener commonly used in processed foods could be increasing people’s risk of heart attack and stroke, a new study argues.
Erythritol is a natural sugar alcohol found in many vegetables and fruit. Even...
Source: Drugs.com - Daily MedNews - February 27, 2023 Category: General Medicine Source Type: news
MRI for all: Cheap portable scanners aim to revolutionize medical imaging
.news-article__hero--featured .parallax__element{ object-position: 47% 50%; -o-object-position: 47% 50%; }
The patient, a man in his 70s with a shock of silver hair, lies in the neuro intensive care unit (neuro ICU) at Yale New Haven Hospital. Looking at him, you’d never know that a few days earlier a tumor was removed from his pituitary gland. The operation didn’t leave a mark because, as is standard, surgeons reached the tumor through his nose. He chats cheerfully with a pair of research associates who have come to check his progress with a new and potentially revolutionary device they are testing.
The cylind...
Source: Science of Aging Knowledge Environment - February 23, 2023 Category: Geriatrics Source Type: research
Identifying patients at risk: multi ‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices
ConclusionsHM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2 years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Source: ESC Heart Failure - February 17, 2023 Category: Cardiology Authors: Lieke Numan,
Daniel Zimpfer,
Osnat Itzhaki Ben Zadok,
Emmeke Aarts,
Michiel Morshuis,
Sabina P.W. Guenther,
Julia Riebandt,
Dominik Wiedemann,
Faiz Z. Ramjankhan,
Anne ‐Marie Oppelaar,
Tuvia Ben‐Gal,
Binyamin Ben‐Avraham,
Folkert W. Asse Tags: Original Article Source Type: research
Theory of Pivoting Uncertainties: Advance Care Planning Among Individuals Living With Mechanical Circulatory Support
CONCLUSIONS: In this sample, patients were ready to share their concerns about the uncertainties of living with MCS and waited for MCS clinicians to initiate ACP. The theory of pivoting uncertainties is useful for elucidating the ebb and flow of ACP and lending clinicians' guidance for opportunities to initiate these sensitive conversations.PMID:36563323 | DOI:10.1097/JCN.0000000000000960
Source: The Journal of Cardiovascular Nursing - December 23, 2022 Category: Nursing Authors: Tiffany Dzou Jo-Ann Eastwood Lynn Doering Carol Pavlish Huibrie Pieters Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Waitlist and transplant outcomes for patients bridged to heart transplantation with Impella 5.0 and 5.5 devices
ConclusionsImpella devices can be used as a BTT with excellent survival and minimal post-transplant morbidity. Outcomes were comparable for Impella 5.0 and 5.5 devices.
Source: Journal of Cardiac Surgery - November 15, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Morgan A. Hill,
Jennie H. Kwon,
Khaled Shorbaji,
Arman Kilic Tags: ORIGINAL ARTICLE Source Type: research
